Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placeboPASP · people with pulmonary hypertension group 2 ‐ 41 finding from 1 reviewPhosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 146 participantsModerate